AMENDMENTS TO THE CLAIMS

1-15. (Cancelled)

16. (Withdrawn) The composition for solubilization of paclitaxel according claim 85, wherein the calcium channel blocker is chosen from verapamil and a dihydropyridine chosen from nifedipine, nicardipine and nitrendipine; wherein the calmodulin antagonist is chosen from trifluoroperazine; wherein the antihypertensive is reserpine; wherein the Vinca alkaloid is chosen from vincristine and vinblastine; wherein the steroid is progesterone; wherein the antiarrhythmic is chosen from amiodarone and quinidine; wherein the anthelmintic is chosen from quinacrine and quinine; and wherein the immunosuppressant is chosen from cyclosporine A, staurosporine and tacrolimus.

17-27. (Cancelled)

28. (Withdrawn) A method of preparing the composition for solubilization of paclitaxel according to claim 78, wherein said method comprises the steps of:

(1) solubilizing 40 to 89.9% by weight of monoolein in 10 to 59.9% by weight of an oil chosen from triglyceride, iodized oil, vegetable oil and animal oil; and

(2) solubilizing completely 0.01 to 10% by weight of paclitaxel in said mixture in step (1) by stirring.

29-77. (Cancelled)

78. (Previously Presented) A solubilized paclitaxel composition consisting essentially of:

1) 40 to 89.9% by weight of monoolein;

2) 10 to 59.99% by weight of an oil chosen from triglyceride, iodized oil, vegetable oil and animal oil; and

3) 0.01 to 10% by weight of paclitaxel.

79. **(Currently Amended)** A solubilized paclitaxel composition consisting essentially of:

1) 40 to 89.9% by weight of monoolein;

2) 10 to 59.99% by weight of an oil chosen from triglyceride, iodized oil, vegetable oil and animal oil; and

3) 0.01 to 10% by weight of paclitaxel; and

4) 0.01 to 5 % by weight of additive, wherein the additive is selected from the group consisting of an anticancer drug, ~~a p-glycoprotein~~ a p-glycoprotein inhibitor and a hepatic metabolism blocker.

80. (Previously Presented) A solubilized paclitaxel composition consisting essentially of:

1) 40 to 89.9% by weight of monoolein;

2) 10 to 59.99% by weight of an oil chosen from triglyceride, iodized oil, vegetable oil and animal oil;

3) 0.01 to 10% by weight of paclitaxel; and

4) 0.01 to 90% by weight of at least one emulsifier.

81. (Previously Presented) The solubilized paclitaxel composition according to any one of claims 78 to 80,

wherein said triglyceride is chosen from saturated and unsaturated triglycerides having 2 to 20 carbon atoms in each hydrocarbon chain.

82. (Previously Presented) The solubilized paclitaxel composition according to any one of claims 78 to 80,

wherein said triglyceride is chosen from triacetin, tributyrin, tricaproin, tricaprylin, tricaprin and triolein;

wherein said iodized oil is chosen from Lipiodol, iodized poppy seed oil, Ethiodol and iodized soybean oil;

wherein said vegetable oil is chosen from soybean oil, cottonseed oil, olive oil, poppyseed oil, linseed oil and sesame oil; and

wherein said animal oil is chosen from squalane and squalene.

83. (Previously Presented) The solubilized paclitaxel composition according to any one of claims 78 to 80,

wherein the composition is suitable for oral administration, buccal administration, mucosal administration, intranasal administration, intraperitoneal administration, subcutaneous injection, intramuscular injection, transdermal administration, or intratumoral injection.

84. (Previously Presented) The solubilized paclitaxel composition according to any one of claims 78 to 80,

wherein the composition is liquid or semi-solid state at room temperature.

85. (Previously Presented) The solubilized paclitaxel composition according to claim 79,

wherein the anticancer drug is chosen from doxorubicin, cisplatin, carboplatin, carmustin (BCND), dacarbazine, etoposide, 5-fluorouracil and a paclitaxel derivative chosen from docetaxel, bromotaxel and taxotere; wherein said p-glycoprotein inhibitor is chosen from cinchonin, a calcium channel blocker, a calmodulin antagonist, an antihypertensive, a Vinca alkaloid, a steroid, an antiarrhythmic, an anthelmintic and an immunosuppressant; and wherein said hepatic metabolism blocker is chosen from an anticancer drug chosen from cyclosporin A, doxorubicin, etoposide (VP-16) and cisplatin, verapamil and tamoxifen.

86. (Previously Presented) The solubilized paclitaxel composition according to claim 80,

wherein said emulsifier is chosen from a phospholipid, a non-ionic surfactant, an anionic surfactant, a cationic surfactant and bile acid.

87. (Previously Presented) The solubilized paclitaxel composition according to claim 86,

wherein said phospholipid is chosen from a phosphatidylcholine (PC) and its derivative, a phosphatidylethanolamine (PE) and its derivative, a phosphatidylserine (PS) and its derivative, and a polymeric lipid wherein a hydrophilic polymer is conjugated to the lipid headgroup;

wherein said non-ionic surfactant is chosen from a poloxamer (polyoxyethylene-polyoxypropylene copolymer), a sorbitan ester (sorbitan esters), a polyoxyethylene sorbitan and a polyoxyethylene ether;

wherein said anionic surfactant is chosen from a phosphatidylserine (PS) and its derivative, a phosphatidic acid (PA) and its derivative, and sodium dodecyl sulfate (SDS);

wherein said cationic surfactant is chosen from 1,2-dioleyl-3-trimethylammonium propane (DOTAP), dimethyldioctadecylammonium bromide (DDAB), N-[1-(1,2-dioleyloxy)propyl]-N,N,N-trimethylammonium chloride (DOTMA), 1,2-dioleyl-3-ethylphosphocholic acid (DOEPC) and 3β-[N[(N',N'-dimethylamino)ethan]carbarnoyl] cholesterol (DC-Chol); and

wherein said bile acid is chosen from cholic acid, its salt and derivatives; deoxycholic acid, its salt and derivatives; chenocholic acid, its salt and derivatives; and lithocholic acid, its salt and derivatives.

88. (Previously Presented) The solubilized paclitaxel composition according to claim 78, consisting of:

1) 40 to 89.9% by weight of monoolein,

2) 10 to 59.99% by weight of an oil chosen from triglyceride, iodized oil, vegetable oil and animal oil, and

3) 0.01 to 10% by weight of paclitaxel,

wherein the solubilized paclitaxel composition is a lipid-based oral formulation.

89. **(Currently Amended)** The solubilized paclitaxel composition according to claim 79, consisting of:

1) 40 to 89.9% by weight of monoolein,

2) 10 to 59.99% by weight of an oil chosen from triglyceride, iodized oil, vegetable oil and animal oil, and

3) 0.01 to 10% by weight of paclitaxel, and

4) 0.01 to 5 % by weight of additive, wherein the additive is selected from the group consisting of an anticancer drug, ~~a p-glycoprotein~~ a p-glycoprotein inhibitor and a hepatic metabolism blocker, and

wherein the solubilized paclitaxel composition is a lipid-based oral formulation.

90. (Previously Presented) The solubilized paclitaxel composition according to claim 80, consisting of:

1) 40 to 89.9% by weight of monoolein,

2) 10 to 59.99% by weight of an oil chosen from triglyceride, iodized oil, vegetable oil and animal oil,

3) 0.01 to 10% by weight of paclitaxel, and

4) 0.01 to 90% by weight of at least one emulsifier,

wherein the solubilized paclitaxel composition is a lipid-based oral formulation.

91. **(Cancelled)**